close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvation Bio Inc. Class A Common Stock (NY:NUVB)

4.585 +0.075 (+1.66%)
Streaming Delayed Price Updated: 10:15 AM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nuvation Bio Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Analyst Expectations for Nuvation Bio's Future ↗
 
Via Benzinga
News headline image
Where Nuvation Bio Stands With Analysts ↗
 
Via Benzinga
News headline image
The 7 Worst Stocks to Buy Now ↗
With the market reeling from the banking crisis, even hardened gamblers should avoid these worst stocks to buy now. 
Via InvestorPlace
News headline image
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
News headline image
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868
From Nuvation Bio Inc.
Via Business Wire
News headline image
Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
News headline image
After FDA Hold, Nuvation Bio Stops NUV-422 Cancer Development Program ↗
 
Via Benzinga
News headline image
Short Volatility Alert: Nuvation Bio Inc. ↗
On Friday, shares of Nuvation Bio Inc. (NYSE: NUVB) experienced volatile short activity. After the activity, the stock price went up +0% to $4.04. The overall sentiment for NUVB has been Bearish. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023 ↗
 
Via Benzinga
News headline image
FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 64 companies achieved new lows for the year. 
Via Benzinga
News headline image
Netflix Price Target Cut By This Analyst, Plus Morgan Stanley Predicts $403 For McKesson ↗
UBS cut the price target for Coupa Software Incorporated (NASDAQ: COUP) from $84 to $76. Coupa Software shares fell 4.9% to $64.44 in pre-market trading. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 70 companies set new 52-week lows. 
Via Benzinga
News headline image
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  Wednesday's session saw 51 companies set new 52-week lows. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 92 companies set new 52-week lows. 
Via Benzinga
News headline image
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
From Nuvation Bio Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 108 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 100 companies reached new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  During Friday's session, 61 companies made new 52-week lows. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Biophytis (NASDAQ:BPTS) stock moved upwards by 15.8% to $0.95 during Monday's after-market session. The company's market cap stands at $15.5 million. 
Via Benzinga
News headline image
Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer
From Nuvation Bio Inc.
Via Business Wire
News headline image
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors
From Nuvation Bio Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
News headline image
77 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today